-
-
-
-
-
-
-
Corvus Pharmaceuticals' (CRVS) Demonstrates Improvements in EASI - Cantor Fitzgerald
-
-
-
-
-
-
-
Corvus Pharma (CRVS) Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
-
-
-
-
-
-
-
Corvus Pharmaceuticals, Inc. (CRVS) Misses Q4 EPS by 6c
-
-
-
-
-
-
-
Corvus Pharma (CRVS) Falls 15% Following Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
-
-
-
-
-
-
-
Corvus Pharmaceuticals, Inc. (CRVS) Misses Q3 EPS by 49c
-
-
-
-
-
-
-
Corvus Pharma (CRVS): Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

